



ImmunoCard[®]

MYCOPLASMA

REF Catalogue Number 709030

IVD *In vitro* diagnostic medical device

A Rapid Enzyme Immunoassay for the Detection of IgM to *Mycoplasma pneumoniae* in Human Serum

INTENDED USE

The ImmunoCard Mycoplasma enzyme immunoassay (EIA) is an *in vitro* qualitative procedure for the detection of IgM to *Mycoplasma pneumoniae* in human serum. Test results are intended to aid in the diagnosis of recent *Mycoplasma pneumoniae* infection.

SUMMARY AND EXPLANATION OF THE TEST

Mycoplasma pneumoniae is a member of a group of degenerate bacteria lacking a cell wall.¹ *M. pneumoniae* was the first human pathogen identified in the group and causes up to 20% of all cases of pneumonia.^{1,2} Mycoplasmal pneumonia presents with flu-like symptoms,³ however unlike most viral and bacterial pneumonias, mycoplasmal pneumonia is more gradual in both presentation and recovery. *M. pneumoniae* infections are usually grouped in the category of atypical pneumonia. Examples of other organisms which cause atypical pneumonia are influenza (A and B), respiratory syncytial virus, adenovirus, parainfluenza, cytomegalovirus, *Chlamydia*, *Legionella*, *Histoplasma capsulatum* and *Coccidioides immitis*.³ *M. pneumoniae* disease progression is usually limited to the respiratory system from the naso-pharynx through bronchioles; resulting in widely varying symptoms more consistent with bronchitis than pneumonia. Antibiotics may ameliorate symptoms, however organism can often be cultured from patients following antibiotic regimes. Asymptomatic (silent) infections may occur in adults and account for up to 20% of *M. pneumoniae* infections.⁴

M. pneumoniae is endemic, with minimal seasonal variation (small increases in the late summer/early fall).^{2,5} Incidence overall ranges from 0.5 to 5.0 per 1,000 population or up to 20% of all pneumonias. Incidence peaks with 5-9 year olds and declines with age except for a slight rise in the 30-40 year age group. The disease is rare in adults over 50 and infants, although the impact may be severe in these groups. The organism appears to require close contact for transmission. Development of symptoms may take several weeks, and transmissible organism may persist once symptoms have subsided. Epidemics occur in 4 to 7-year cycles world wide and may be linked to childhood school and day-care facilities.^{5,6}

Direct detection of *Mycoplasma pneumoniae* infection is currently difficult, owing the slow growth (4-20 days) of the organism in culture and fastidious growth requirements.¹ For this reason, serology is often the best laboratory method available.^{7,8} The complement fixation (CF) test identifies antibody to a mycoplasmal lipopoly saccharide (LPS). In general, laboratories suggest that four-fold increases in CF titer using paired acute/convalescent sera, or CF titers ≥ 64 are diagnostic. Other serological tests include enzyme immunoassays (EIAs) and immunofluorescent assays (IFAs) for the detection of IgG or IgM, and detection of cold agglutinins. The advantage of an IgM based assay is the detection of early/acute illness rather than convalescent disease where the switch to IgG has occurred.

The presence of IgM to *M. pneumoniae* is considered to have a role in the diagnosis of early/acute disease.^{4,9,10,11} Tests which detect both IgM and IgG or tests which detect IgG only have the problem of being positive in convalescent patients, as well as in individuals with previous history of *M. pneumoniae* disease (subclinical).

The ImmunoCard Mycoplasma methodology provides a simple to use, self-contained device. No calculations are required and the visual color change makes interpretation of results objective and simple.

PRINCIPLE OF THE TEST

The ImmunoCard Mycoplasma EIA detects the presence of IgM to *M. pneumoniae* in serum. Patient serum is added to each of the two sample ports. After allowing the sample to enter the device and migrate along the membrane and through the reaction ports, three drops of anti-human IgM alkaline phosphatase conjugate are added to the sample ports and allowed to enter the device. Three drops of wash and two drops of substrate are then added to each of the reaction ports. Reaction ports are observed for the development of any blue color after five minutes. The **CONTROL** port serves as a procedural control, containing immobilized human IgM in the reaction port. The **TEST** port contains *M. pneumoniae* antigens and serves as the patient test port. The development of blue color in the **TEST** port indicates a reactive test result for IgM to *M. pneumoniae*. No blue color in the **TEST** port indicates a nonreactive result.

REAGENTS/MATERIALS PROVIDED

1. **Test Cards** - Individually foil pouched cards containing immobilized detergent extracted *M. pneumoniae* antigens (**TEST** reaction port) and human IgM (**CONTROL** reaction port)
2. **Positive Control** - Sample containing human anti-*M. pneumoniae* IgM in a buffer containing 0.1% sodium azide
3. **Negative Control** - Buffer containing 0.1% sodium azide
4. **Enzyme Conjugate** - Monoclonal anti-human IgM labeled with alkaline phosphatase in a buffer containing 0.1% sodium azide
5. **Wash Buffer** - Buffer containing 9.5% (weight/vol.) guanidine hydrochloride
6. **Substrate Reagent** - Buffered solution containing 5-bromo-4-chloro-3-indolyl phosphate and 0.1% sodium azide
7. **Transfer Pipettes**

The maximum number of tests obtained from this test kit is listed on the outer box.

MATERIALS NOT PROVIDED

Timer

PRECAUTIONS

1. All reagents are for *in vitro* diagnostic use only.
2. Reagent concentration, incubation times and temperatures (22-25 C) have been optimized for sensitivity and specificity. Best results are obtained by adhering to these specifications. Once the assay has been started, complete all subsequent steps without interruption.
3. The right reaction (upper) port has been coated with extracted *Mycoplasma* antigens. Handle as a potentially hazardous material.
4. Patient specimens, Positive Control reagent, and used Test Cards may contain infectious agents and should be handled at Biosafety Level 2 as recommended in the CDC/NIH manual "Biosafety in Microbiology and Biomedical Laboratories"; 2007.
5. The Positive Control contains human sera, which were screened for HBsAg and antibody to HIV-1 and found to be negative. However, no test can offer complete assurance that human blood will not transmit HIV, hepatitis, or other infectious agents.
6. All reagents should be gently mixed and at 22-25 C before use.
7. Do not interchange reagents from different kit lot numbers or use expired reagents.
8. Hold reagent vials and transfer pipettes vertically to insure proper drop size and delivery. Do not allow the tips of the bottle or pipette to touch either the sample or reaction ports.
9. Replace colored caps on correct vials.
10. Substrate Reagent may be light sensitive and should not be exposed to excessive illumination. Substrate Reagent should be colorless. If this reagent exhibits a blue color, it should be discarded.
11. Use only one transfer pipette per control or specimen. Discard after use. Do not attempt to reuse.
12. Disregard any color reactions in the sample (lower) ports. Results are determined by color development in the reaction (upper) ports.
13. Severely lipemic serum, contaminated serum, or serum with excessive debris may restrict movement of Enzyme Conjugate into the sample (lower) ports, potentially producing an invalid result. Noncontaminated serum causing flow problems (invalid results) may be centrifuged and retested.
14. Specimens with obvious microbial contamination or severe hemolysis should not be tested as they may yield unreliable results.
15. Patient samples should not be allowed to dry in the sample application ports. Drying of whole blood or serum onto filter paper inactivates, to varying extents, IgM class antibodies.¹²

WARNING: Some reagents in this kit contain sodium azide which is a skin irritant. Avoid skin contact with reagents. Disposal of reagents containing sodium azide into lead or copper plumbing can result in the formation of explosive metal azides. This can be avoided by flushing with a large volume of water during such disposal.

RISK AND SAFETY PHRASES

Substrate, Negative Control, Enzyme Conjugate, Positive Control: HARMFUL – SODIUM AZIDE

RISK PHRASES:

- 22 Harmful if swallowed
- 32 Contact with acids liberates very toxic gas

STORAGE AND STABILITY

The expiration date is indicated on the kit label. Store the kit at 2-8 C and return the kit promptly to the refrigerator after each use.

SPECIMEN COLLECTION AND PREPARATION


Serum specimens obtained from clotted blood should be stored at 2-8 C until tested. The specimen should be tested as soon as possible but may be held up to 72 hours at 2-8 C prior to testing. If testing cannot be performed within this time frame, the specimen should be frozen in a nondefrosting freezer (-20 C or lower) immediately upon receipt. Repeated freezing and thawing of specimens should be avoided.

REAGENT PREPARATION

1. Allow all kit components to reach room temperature (22-25 C) before use (requires at least one hour). Gently mix liquid reagents prior to use.
2. All reagents come ready to use (no dilution required)

PROCEDURAL NOTES

1. The Test Card format is diagrammed below:




2. Batch processing any number of samples or controls is possible provided that *for each card*, the appropriate steps, sequence of reagent addition, incubation (wait) times and result reading time are maintained. Each procedural step should be completed with each sample before the next step is started.
3. The **CONTROL** (left) side of each card provides a procedural control for each specimen. This tests for proper specimen and reagent flow characteristics as well as reagent performance.

TEST PROCEDURE

This test should be performed by qualified personnel per local regulatory requirements.

1. Remove the appropriate number of Test Cards from their envelopes. Label with appropriate identification. Use 1 Test Card for each control or sample to be tested.
2. Using a transfer pipette, dispense 2 drops of serum to both lower sample ports.
3. Incubate 2 minutes at 22-25 C. Note: during the 2-minute incubation, specimen must adsorb completely and cover both reaction (upper) ports.
4. Add 3 drops of Enzyme Conjugate to both sample (lower) ports. Incubate 2 minutes at 22-25 C. Enzyme Conjugate should completely absorb during the incubation period.
5. Add 3 drops of Wash Buffer to both reaction (upper) ports. Wait until wash buffer has absorbed completely.
6. Add 2 drops of Substrate Reagent to both reaction (upper) ports. Start a timer for 5 minutes when substrate is added to the first Card. Incubate for 5 minutes at 22-25 C. Visually read results immediately at the end of the incubation period.

INTERPRETATION OF RESULTS



Reactive Test Result: Visually detectable blue color in **BOTH** reaction ports. Occasionally a reactive test result may show evidence of a gradation of blue color within the reaction port. A reactive result indicates the presence of IgM to *M. pneumoniae*.

Nonreactive Test Result: Visually detectable blue color in **CONTROL** reaction port (upper left) only. The **TEST** reaction port (upper right) should be colorless to faint grey. Occasionally, the **TEST** reaction port (upper right) may show evidence of a hint of blue color in the right or left side of the port, with the rest of the port remaining colorless. This should be considered a nonreactive test result. Nonreactive results indicate either the absence of IgM to *M. pneumoniae*, or levels below the limit of detection for the assay.

Invalid Test Result: No detectable color in **CONTROL** reaction port (upper left). Invalid test results may be due to a reagent/Test Card problem, a procedural error, or restriction of flow of sample and/or Enzyme Conjugate due to severely contaminated, lipemic or debris containing serum. Noncontaminated serum may be centrifuged and retested.

QUALITY CONTROL

The Positive and Negative Controls should be assayed upon receipt of the kit. Add two drops of Positive Control to both lower Sample ports of a card. Add two drops of Negative Control to both lower Sample ports of a second card. Follow Steps 3 through 6 in the Procedure Section.

1. **Positive Control:** Must yield visually detectable blue color in both reaction (upper) ports.
2. **Negative Control:** Must yield visually detectable blue color in **CONTROL** (upper left) reaction port only. The **TEST** (upper right) reaction port should be colorless.

The **Procedural Control** present in the upper left port of each Test Card tests the individual specimen for proper flow and reagent performance. Failure of the **Procedural Control** to yield a blue color with any specimen or control reagent indicates an invalid test result and the test should be repeated.

At the time of each use, kit components should be visually examined for obvious signs of microbial contamination, freezing, or leakage.

Repeat the control tests as the first step in determining the root cause of the failure.

It is suggested that the results of each quality control check be recorded in an appropriate log book to maintain high quality testing records. If the expected reactions are not observed and the reagents are still within their expiration date, please contact Meridian Bioscience's Technical Support Services at 513-271-3700 or 800-343-3858 (for US only) or contact your Country/Local Distributor.

EXPECTED VALUES

The ImmunoCard Mycoplasma test was evaluated at four hospitals throughout the midwest. In addition, a reference lab tested specimens from throughout the country. Of the 160 prospective specimens tested at the hospital sites, 26 (16%) were positive by the ImmunoCard Mycoplasma test. The reference laboratory reported 85/352 (24%) ImmunoCard Mycoplasma positive specimens. These results were consistent with results obtained using other IgM tests for *M. pneumoniae*, as well as published findings for the prevalence of IgM to *M. pneumoniae*.^{1,2,13,14} When a group of blood bank sera was tested for IgM to *M. pneumoniae* using the ImmunoCard Mycoplasma and a reference EIA, a prevalence of 12.7% and 16% was found by each method, respectively.

LIMITATIONS OF THE PROCEDURE

1. ImmunoCard Mycoplasma test results should be used in conjunction with information available from the patient clinical evaluation and other available diagnostic procedures.
2. Samples obtained too early during infection may not contain detectable levels of IgM antibody. If a *M. pneumoniae* infection is suspected, a second sample should be obtained in 7-14 days and tested.
3. Significance of test results of immunosuppressed patients may be difficult to interpret.
4. Positive test results may not be valid in persons who have received blood transfusions or other blood products within the past several months.
5. Specific IgM antibodies to *M. pneumoniae* are usually detected in patients with a recent primary infection. However, they may be found in patients with reactivated or secondary infections and are sometimes found in patients with no other detectable evidence of recent infection.^{7,11} In addition, IgM to *M. pneumoniae* has been shown to persist for extended periods (2-12 months) in some patients.¹¹
6. False negative results due to competition by high levels of IgG, while theoretically possible, have not been observed.

SPECIFIC PERFORMANCE CHARACTERISTICS

The ImmunoCard Mycoplasma test was evaluated using sera at three hospitals and one reference laboratory. ImmunoCard Mycoplasma results were compared with a microwell EIA for IgM to *M. pneumoniae*. Discrepant results were resolved by IFA, latex and complement fixation testing.

ImmunoCard	Reference EIA			Resolved		
	Reactive	Nonreactive	Retest	Reactive	Nonreactive	Retest
Reactive	69	45	16	88	29	13
Nonreactive	27	245	12	12	268	4

Relative Sensitivity 88% ± 6%¹
 Relative Specificity 90% ± 3%
 Relative Agreement 90% ± 3%

¹ ± values calculated as 95% confidence intervals using the normal method.

Forty-five ImmunoCard Mycoplasma reactive specimens, which were nonreactive by the reference EIA had 14 reactive, 26nonreactive, and five unresolved results. Sixteen sera with reactive ImmunoCard and indeterminate reference EIA results had five reactive, three nonreactive, and eight unresolved results.

Twenty-seven specimens with ImmunoCard nonreactive, reference EIA reactive results had 11 reactive, 14 nonreactive, and two unresolved results. Finally, 12 ImmunoCard nonreactive, reference EIA indeterminate specimens had one reactive, nine nonreactive, and two unresolved results. No ImmunoCard Mycoplasma invalid test results were obtained during clinical trials compared to 28/414 or a 6.8% retest rate for the reference EIA method.

Two of the clinical trial sites (one hospital and a reference lab) performed complement fixation titration for antibody to *M. pneumoniae*. CF results were grouped as nonreactive (< 1/8), low (1/8-1/32), and reactive (≥1/64). ImmunoCard Mycoplasma results were compared with CF titers in the table below.

ImmunoCard	CF Titer		
	< 8	8-32	≥ 64
Reactive	29	25	28
Nonreactive	97	56	4

The ImmunoCard Mycoplasma test correctly identified 28/32 (88%) of the high titer (≥ 64) CF specimens. The ImmunoCard test was reactive with 25 (31%) of the low titer CF (8-32) specimens. Twenty-four (96%) of these were confirmed as IgM reactive by other methods. Finally, 25/29 (86%) CF nonreactive specimens were found reactive by ImmunoCard Mycoplasma and were also reactive by either EIA or IFA.

ANALYTICAL SPECIFICITY

The specificity of the ImmunoCard Mycoplasma test was evaluated on retrospective specimens from patients with positive culture or with serological evidence for other atypical pneumonias, as well as viral, bacterial, and fungal pneumonias. Specimens positive for rheumatoid factor, anti-nuclear antibody and lupus were also tested. One of four lupus specimens was ImmunoCard Mycoplasma reactive. No cross-reactions were observed with the other classes of sera listed below. Values in parentheses indicate the number of sera tested.

Histoplasma (5)	Cytomegalovirus (6)	Coccidioides (10)	Epstein Barr Virus (14)
Parainfluenza 3 (1)	Legionella (7)	Influenza A (13)	Chlamydia (9)
Influenza B (1)	Antinuclear Antibody (20)	Respiratory Syncytial Virus (1)	Rheumatoid Factor (10)
Adenovirus (3)			

ITALIANO



REF Numero di catalogo 709030

IVD Dispositivo medico-diagnostico *in vitro*

Test rapido immunoenzimatico per la ricerca delle IgM anti-*Mycoplasma pneumoniae* nel siero

FINALITÀ D'USO

L' ImmunoCard Mycoplasma è un test immunoenzimatico (EIA) che consente la ricerca qualitativa *in vitro* delle IgM anti-*Mycoplasma pneumoniae* (MP) nel siero. I risultati di tale esame rappresentano un aiuto nella diagnostica delle infezioni acute o recenti causate da *Mycoplasma pneumoniae*.

RIASSUNTO E SPIEGAZIONE DEL TEST

Mycoplasma pneumoniae appartiene ad un gruppo di batteri, i *Mollicuti*, caratterizzati dalla mancanza della parete cellulare.¹ *M. pneumoniae* è stato il primo componente di questo gruppo ad essere identificato come patogeno umano ed attualmente è ritenuto responsabile di una percentuale abbastanza consistente (fino al 20%) dei casi di infezioni polmonari.^{1,2} La polmonite da Mycoplasma si presenta con una sintomatologia simile a quella dell'influenza,³ tuttavia, a differenza della maggior parte delle polmoniti ad eziologia batterica e virale, essa è caratterizzata da un' maggiore gradualità, sia nell'insorgenza dei sintomi che nella guarigione. Le infezioni causate da *M. pneumoniae* vengono normalmente classificate tra le polmoniti atipiche, che raggruppano quelle indotte da un' ampia gamma di microrganismi, tra cui virus influenzale (A e B), Virus Respiratorio Sinciziale, Adenovirus, Parainfluenza, Cytomegalovirus, *Chlamydia*, *Legionella*, *Histoplasma capsulatum* e *Coccidioides immitis*.³ La diffusione dell'infezione da *M. pneumoniae* è normalmente limitata alla parte dell'apparato respiratorio compresa tra la zona rinofaringea ed i bronchioli, con una conseguente sintomatologia molto variabile, più simile ad una bronchite che non ad una polmonite. La terapia antibiotica può alleviare i sintomi, tuttavia spesso è possibile isolare in coltura *M. pneumoniae* anche dopo il trattamento. Nei pazienti adulti si possono osservare anche infezioni asintomatiche (silenti), con una percentuale che può arrivare anche al 20% del totale di polmoniti da *M. pneumoniae*.⁴